Call +41-61-926-60-40 Fax +41-61-926-60-49

BLZ-945

AG-CR1-3609-M001 1 mg INQ
AG-CR1-3609-M005 5 mg INQ
AG-CR1-3609-M025 25 mg INQ
Actions
Select size:

* Required Fields

Amount:
Add to Cart
Call +41-61-926-60-40
Fax +41-61-926-60-49
Contact Us!

Additional Information

Product Data
Synonyms BLZ945
Properties
Formula C20H22N4O3S
MW 398.5
CAS 953769-46-5
Purity ≥95%
Appearance Pale yellow solid.
Solubility Soluble in DMSO. Slightly soluble in ethanol. Insoluble in water.
InChi Key ADZBMFGQQWPHMJ-RHSMWYFYSA-N
Product Type Chemical
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download Document Download

Product Description

  • Anticancer compound.
  • Orally active, potent and selective colony stimulating factor 1 receptor (CSF-1R; c-Fms) inhibitor.
  • More than 1000-fold selective against its closest receptor tyrosine kinase homologs c-KIT and platelet-derived growth factor receptor β (PDGFRβ).
  • Selective against more than 200 additional kinases [2].

Product References

  1. Investigation of correlation among safety biomarkers in serum, histopathological examination, and toxicogenomics: T. Wang, et al.; Int. J. Toxicol. 30, 300 (2011)
  2. CSF-1R inhibition alters macrophage polarization and blocks glioma progression: S.M. Pyonteck, et al.; Nat. Med. 19, 1264 (2013)
  3. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells: D.C. Strachan, et al.; Oncoimmunology 2, e26968 (2013)
  4. Therapeutically reeducating macrophages to treat GBM: C. Garris & M.J. Pittet; Nat. Med. 19, 1207 (2013)
  5. Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite: J.A. Krauser, et al.; Xenobiotica 45, 107 (2015)
No reviews for this product yet.